
    
      This is a randomized, double-blind, placebo controlled, multicenter, multinational efficacy
      and safety study in subjects with non small cell lung cancer (NSCLC). Subjects will be evenly
      randomized to placebo or GTx-024 prior to initiation of first line chemotherapy. The primary
      efficacy analysis will be based on total lean body mass and physical function.
    
  